IBRX Q1 2021 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena

IBRXImmunityBio, Inc.

$8B

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$139,000-15.8% YoY

Gross Profit

$139,000100.0% margin

Operating Income

-$86M-62060.4% margin

Net Income

-$80M-57276.3% margin

EPS (Diluted)

$-0.21

QoQ Revenue Growth

+561.9%

Cash Flow

Operating Cash Flow

-$60M

Free Cash Flow

-$68M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$209M

Total Liabilities

$395M

Stockholders' Equity

-$186M

Cash & Equivalents

$45M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$139,000	$165,000	-15.8%
Gross Profit	$139,000	$165,000	-15.8%
Operating Income	-$86M	-$37M	-135.0%
Net Income	-$80M	-$37M	-115.0%